Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

AIM ImmunoTech Inc

Asensus Surgical

iBio

Jaguar Health

Ovid Therapeutics

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Company's Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has been accepted for presentation at the Virtual Annual Meeting on Women's Cancer, sponsored by the Society of Gynecologic Oncology.

Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer

LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference, being held March 15 – 17, 2021. A webcast of Celsion's presentation will be pre-recorded and will be available on the Company's website during the week before the conference.

Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference

Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy.

Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years

Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Celsion (CLSN) stock was on the rise Monday after announcing fast-track approval from the U.S. Food and Drug Administration. The post CLSN Stock: Why Biotech Celsion Is Soaring Today appeared first on InvestorPlace.

CLSN Stock: Why Biotech Celsion Is Soaring Today

Celsion Receives Fast Track Tag In US For Ovarian Cancer Immunotherapy

The stock price of Celsion Corporation (NASDAQ: CLSN) is trading at over 50% pre-market. This is why it happened.

CLSN Stock Price Increases Over 50% Pre-Market: Why It Happened

Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases  Granted an Accelerated Development Pathway

Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2

Celsion Corporation Announces Formation of Vaccine Advisory Board

Celsion (CLSN) stock is rising higher on Thursday after the release of a letter from chairman, president and CEO Michael Tardugno. The post CLSN Stock: Why Biotech Company Celsion Is Soaring Today appeared first on InvestorPlace.

CLSN Stock: Why Biotech Company Celsion Is Soaring Today

The stock price of Celsion Corporation (NASDAQ: CLSN) has increased by over 16% pre-market. This is why it happened.

CLSN Stock Price Increases Over 16% Pre-Market: Why It Happened

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?

Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules, resulting in net proceeds of $32.6 million, after deducting placement agents' fees but before expenses payable by the Company.

CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of $1.35 per share in a registered direct offering, priced at-the-market under Nasdaq rules, for gross proceeds of $35 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about January 26, 2021, subject to the satisfaction of customary closing conditions.

CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

Celsion Corporation (NASDAQ: CLSN) shares are trading at their highest level since early July after the company terminated a stock sale agreement. Celsion revealed in SEC filing it has notified Lincoln Park Capital Fund regarding termination of the stock purchase agreement signed between both parties on Sept.

Why Celsion's Stock Is Ripping Higher Today

Celsion (CLSN) stock is soaring higher Thursday on heavy trading and InvestorPlace has all the details investors need to know. The post CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar appeared first on InvestorPlace.

CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar

Shares of Celsion Corp. shot up 85.1% toward a six-month high in very active premarket trading Thursday, putting the on track to more than double in two days, after the cancer drug development company disclosed that it terminated the share purchase agreement with Lincoln Park Capital (LPC). Trading volume swelled to 18.9 million shares, enough to make the stock the second-most active ahead of the open, and well above the full-day average of about 4.6 million shares.

Celsion stock rockets on heavy volume again; share sale agreement with LPC was terminated

The stock price of Celsion Corporation (NASDAQ: CLSN) has increased by over 30% pre-market today. This is why it happened.

CLSN Stock Price Increases Over 30% Pre-Market: Why It Happened

LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation.

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) for violations of §§10(b) and 20(a) of the Securities...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.To join the Celsion class action, go...

CLSN Final Deadline Tomorrow: Rosen, Top Ranked National Investor Attorneys, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action - CLSN

NEW YORK, Dec. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”).

DEC. 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN

New York, New York--(Newsfile Corp. - December 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.To join the Celsion class action,...

ROSEN, A TOP RANKED FIRM, Reminds Celsion Corporation Investors of Important Tuesday Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN

News for Celsion Stock (CLSN)